All In Biotech

Drug Trial Radar · NCT04655976

Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

A Randomized, Open Label Phase 2/3 Study Comparing Cobolimab + Dostarlimab + Docetaxel To Dostarlimab + Docetaxel To Docetaxel Alone In Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed On Prior Anti-PD-(L)1 Therapy And Chemotherapy (COSTAR Lung)

Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 758 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

758

Actual

Start

Dec 8, 2020

Primary completion

Jun 5, 2025

Study completion Mar 30, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Dec 7, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, parallel group treatment, Phase 2/3 open label study evaluating cobolimab in combination with dostarlimab and docetaxel in participants with advanced non-small cell Lung Cancer (NSCLC) who have progressed on prior anti-PD-(L)1 therapy and chemotherapy.

Conditions

  • Lung Cancer, Non-Small Cell

Interventions

  • CobolimabBiological

    Cobolimab will be administered.

  • DostarlimabBiological

    Dostarlimab will be administered.

  • DocetaxelDrug

    Docetaxel will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS) (Arm A Versus Arm C)Time frame: Up to approximately 234 weeks
  2. Overall Survival (OS) (Arm B Versus Arm C)Time frame: Up to approximately 234 weeks

Locations

163 sites in 24 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Fountain Valley, California

  • GSK Investigational Site

    Walnut Creek, California

  • GSK Investigational Site

    Norwich, Connecticut

  • GSK Investigational Site

    Washington D.C., District of Columbia

  • GSK Investigational Site

    Honolulu, Hawaii

  • GSK Investigational Site

    Iowa City, Iowa

  • GSK Investigational Site

    Edgewood, Kentucky

  • GSK Investigational Site

    Las Vegas, Nevada

  • GSK Investigational Site

    Mineola, New York

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    White Plains, New York

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Sioux Falls, South Dakota

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Fredericksburg, Virginia

  • GSK Investigational Site

    Tacoma, Washington

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Cipoletti Rio Negro, Argentina

  • GSK Investigational Site

    Ciudad Autonoma de Buenos Aire, Argentina

  • GSK Investigational Site

    Florida, Argentina

  • GSK Investigational Site

    La Rioja, Argentina

  • GSK Investigational Site

    Pergamino, Argentina

  • GSK Investigational Site

    Rosario, Argentina

  • GSK Investigational Site

    Viedma, Argentina

  • GSK Investigational Site

    South Brisbane, Queensland, Australia

  • GSK Investigational Site

    Ashford, South Australia, Australia

  • GSK Investigational Site

    Hobart, Tasmania, Australia

  • GSK Investigational Site

    Ballarat, Victoria, Australia

  • GSK Investigational Site

    Melbourne, Victoria, Australia

  • GSK Investigational Site

    Mount Waverley, Victoria, Australia

  • GSK Investigational Site

    Aalst, Belgium

  • GSK Investigational Site

    Hasselt, Belgium

  • GSK Investigational Site

    Kortrijk, Belgium

  • GSK Investigational Site

    Blumenau, Brazil

  • GSK Investigational Site

    Fortaleza, Brazil

  • GSK Investigational Site

    Porto Alegre, Brazil

  • GSK Investigational Site

    Rio de Janeiro, Brazil

  • GSK Investigational Site

    Rio de Janeiro, Brazil

  • GSK Investigational Site

    Salvador, Brazil

Showing 40 of 163 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.